Skip to content

A clinical study of autologous endometrial functional cells exosome perfusion in endometrial repair treatment

A clinical study of autologous endometrial functional cells exosome perfusion in endometrial repair treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070590
Enrollment
Unknown
Registered
2023-04-17
Start date
2023-04-25
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial injury

Interventions

Group of endometrial injury (Exosome perfusion of uterine cavity):None

Sponsors

Shenzhen Maternity & Child Healthcare Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Age 20-45 years old, female, body mass index 1.1ng/ml; 7. The results of TCT examination were normal within one year or the results of TCT and HPV examination were normal within three years; ? With fully informed consent, the patients voluntarily participated in the study and were able to complete the follow-up on schedule.

Exclusion criteria

Exclusion criteria: 1. Any person suffering from serious cardiovascular, lung, liver and kidney diseases; suffering from chronic diseases: diabetes, hypertension, blood diseases, embolic diseases, autoimmune diseases, etc.; having concomitant diseases that seriously endanger the safety of patients or affect the completion of the study; 2. Uncured STI such as AIDS, syphilis, gonococcus or chlamydia, uncured reproductive tract infectious diseases, and uncured alcoholism, drug abuse and drug addiction; 3. Malignant tumors or suspected malignant tumors; 4. The presence of uterine malformations, adenomyosis, uterine fibroids, endometrial hyperplasia and other uterine organic lesions, the presence of hydrosalpinx or ovarian cysts and other reproductive organ lesions; 5. Currently receiving neuropsychiatric medication; 6. Those who were pregnant before inclusion or had sexual life after menstruation; 7. Use of estrogens, progestogens or antibiotics in the past month; 8. Participating in other clinical trials; 9. Patients who did not sign the informed consent; 10. Other conditions determined by the investigator as unsuitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
Menstrual diary & Symptom diary;Endometrial thickness;

Secondary

MeasureTime frame
Endometrial receptivity microarray;Endometrial microbiome testing;Detection of endometrial immune cells;

Countries

China

Contacts

Public ContactZheng Zheng

Shenzhen Maternity & Child Healthcare Hospital Ethics Committee of Drugs & Medical Devices Clinical Trials

13500056539@139.com+86 13500056539

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026